CDK 4/6 Inhibition in Breast Cancer: Self-Study Module I

Curriculum:
Advanced Clinical Educator Master Class on CDK 4/6 Inhibition in Breast Cancer
Credits:
1 ANCC Contract Hours 1 AMA PRA Category 1 Credit(s)™
Launch Date:
06-Sep-18
Expiration Date:
05-Sep-19

Primary Audience:

Oncology nurses, nurse navigators, nurse practitioners, physician assistants, medical technicians, and other healthcare professionals involved in the care and management of patients with advanced or metastatic breast cancer.

Relevant Terms:

Breast cancer

Theresa W. Gillespie, PhD, MA, RN

Theresa W. Gillespie, PhD, MA, RN
Professor, Department of Surgery and Department of Hematology & Medical Oncology
Emory University School of Medicine
Winship Cancer Institute
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Dr. Gillespie has extensive experience in clinical oncology, clinical trials, and cancer research. She directed oncology clinical research trials in both the community and academic medical center, and was Director of Health Services & Outcomes Research for the Atlanta Veterans Affairs Medical Center. Currently, she is Professor, Department of Surgery and Department of Hematology and Medical Oncology, Emory University School of Medicine; Clinical Associate Professor, School of Nursing; Senior Fellow in the Emory Global Health Institute; and a full member of the Winship Cancer Institute. As Principal Investigator and Co-Investigator on numerous grants, Dr. Gillespie has been funded by the NCI/NIH; CDC; DOD; Veterans Affairs; American Cancer Society, Gates Foundation and Movember Foundation.  Her funded studies have focused on cancer health disparities; decision-making by patients, the public and clinicians; risk communication; quality and outcomes in healthcare; and interventions to improve risk comprehension, guideline concordant care, and outcomes. Dr. Gillespie teaches in the Schools of Medicine, Public Health, and Nursing at Emory and has published and presented broadly for more than 25 years. 
1. Discuss the risks and benefits of CDK 4/6 inhibitors for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer with patients and their families
2. Describe education/shared decision-making strategies to help patients understand their treatment options in estrogen receptor–positive, HER2-negative advanced breast cancer
3. Evaluate proper dosing administration, monitoring, and adherence strategies of CDK 4/6 inhibitors for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer
4. Describe the role of a nurse navigator in the management of patients with advanced or metastatic breast cancer being treated with CDK 4/6 inhibitors

CONTINUING EDUCATION
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
 
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
 
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
 
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
 
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
 
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
 
Theresa Wicklin Gillespie, PhD, MA, RN, has no real or apparent conflicts of interest to report.
 
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
 
The following AXIS planners and managers, Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC and Stephanie Sutphin, PharmD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. 
 
Disclosure of Unlabeled Use                             
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
 
Disclaimer  
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
           
Open Payments Program
As of August 1, 2013, pharmaceutical companies are required by the new Centers for Medicare & Medicaid Services (CMS) Open Payments program (aka, the Physician Payments Sunshine Act) to account for certain transfers of value provided to physicians, including certain meals served to attendees of CME activities, unless specific factors are met.
 
AXIS and its partners have systems in place to fully comply with the Open Payments system. 
 
Safeguards Against Commercial Bias
AXIS Medical Education affirms that the content and format of the certified activity and its related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, AXIS employs several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for certified activities to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation guidelines, and resolution of any actual or perceived conflicts of interest that exist.
 
We employ several metrics during review of content materials, including:
 
  1. Fair balance
a. Recommendations must be based on a reasonable and valid interpretation of the information available on the subject matter
b. No single product or service is overrepresented when other equal, competing products or services are available for inclusion
 
  1. Scientific objectivity of studies mentioned in the activity or used as the basis for content development
 
This activity is supported by an educational grant from Novartis Pharmaceuticals and by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
 
There is no fee for this educational activity.
 
Provided by
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.